Targeting the miR-32533/CREB5 axis: a promising immunomodulatory and therapeutic strategy for Alzheimer’s disease - Takeaways - MDSpire

Targeting the miR-32533/CREB5 axis: a promising immunomodulatory and therapeutic strategy for Alzheimer’s disease

  • By

  • Lizhen Li

  • Xiaolin Zhao

  • Li Zeng

  • Zixuan Li

  • Kaiyue Zhao

  • Zhongdi Cai

  • Rui Liu

  • May 4, 2026

  • 0 min

Share

  • 1

    Alzheimer's disease is the leading cause of dementia, with its incidence projected to triple by 2050, posing significant societal challenges.

  • 2

    miR-32533 is identified as a key regulator in Alzheimer's disease, showing decreased levels in affected brain regions and plasma of patients.

  • 3

    Overexpression of miR-32533 mitigates Aβ-induced neurotoxicity, enhances neuronal survival, and reduces oxidative stress and inflammation.

  • 4

    The miR-32533/CREB5 pathway is crucial in regulating Aβ metabolism, with CREB5 being a direct target of miR-32533 that influences amyloid processing.

  • 5

    Targeting the miR-32533/CREB5 pathway presents a novel therapeutic strategy for addressing multiple pathological aspects of Alzheimer's disease.

Original Source(s)

Targeting the miR-32533/CREB5 axis: a promising immunomodulatory and therapeutic strategy for Alzheimer’s disease

  • by Lizhen Li, Xiaolin Zhao, Li Zeng, Zixuan Li, Kaiyue Zhao, Zhongdi Cai, Rui Liu

  • May 4, 2026

Related Content

A Narrative Review: Do Systemic Drugs Used in the Treatment of Psoriatic Disease Affect Alzheimer’s Disease?

Towards a speech-based digital biomarker for cognitive impairment: speech as a proxy for cognitive assessment

Opposing views or like-minded? International Working Group and Alzheimer’s Association criteria